Greywolf Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology which enhances the activation of T-cells and thereby guides the immune response. Greywolf’s technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. Their mission is to deliver new treatments to improve the lives of people with cancer, autoimmune disorders, and infectious diseases.